Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant-Reference-Cited by-同舟云学术

Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant

Published:2016-08-26 Issue:2 Volume:60 Page:79-88
ISSN:0933-7407
Container-title:Mycoses
language:en
Short-container-title:Mycoses

Author:

Solano Carlos¹^ORCID,Slavin Monica²,Shaul Alissa J.³,Marks David I.⁴,Cordonnier Catherine⁵,Cornely Oliver A.⁶,Pagliuca Antonio⁷,Cragin Lael³,Jarque Isidro⁸,Garcia-Vidal Carolina⁹,Sorensen Sonja³,Vanness David J.¹⁰,Charbonneau Claudie¹¹,Barrueta Jon Andoni¹²,Peral Carmen¹²,De Salas-Cansado Marina¹²,Bow Eric J.¹³

Affiliation:

1. Hospital Clínico; INCLIVA-University of Valencia; Valencia Spain

2. Royal Melbourne Hospital; Melbourne VIC Australia

3. Evidera; Bethesda MD USA

4. University Hospitals Bristol NHS Foundation Trust; Bristol UK

5. Hôpital Henri Mondor; Assistance Publique-Hopitaux de Paris and UPEC; Creteil France

6. Department I of Internal Medicine; Clinical Trials Centre Cologne; Centre for Integrated Oncology Köln Bonn; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases; German Centre for Infection Research; University of Cologne; Cologne Germany

7. King's College Hospital; London UK

8. Hospital Universitari i Politècnic La Fe; Valencia Spain

9. Hospital Universitari de Bellvitge; L'Hospitalet de Llobregat; Barcelona Spain

10. University of Wisconsin and Visiting Scientist at Evidera; Madison WI USA

11. Pfizer Inc; Paris France

12. Pfizer Inc; Madrid Spain

13. CancerCare Manitoba; University of Manitoba; Winnipeg MB Canada

Funder

Pfizer

Publisher

Wiley

Subject